GALT

SEC source: 0001493152-25-019379 · ownership.xml · nonDerivative · entry 1

10X Fund, L.P. · CIK 0001453356 · 10% owner

10X Capital Management, LLC · CIK 0001457247 · 10% owner

CZIRR JAMES C · CIK 0001260641 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,902,207

F1 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001133416-25-000039 · form4.xml · derivative · entry 3

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,706 shares

Expires 2026-01-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F3 · derivative.exercise_date: The options vested as follows: 25% on January 20, 2016, the grant date, with the remainder vesting ratably on a monthly basis over a three year period.

SEC source: 0001133416-25-000039 · form4.xml · nonDerivative · entry 2

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,614

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F2 · price: The shares were sold in multiple transactions at prices ranging from $6.33 to $6.68. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001133416-25-000039 · form4.xml · nonDerivative · entry 1

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,320

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

SEC source: 0001133416-25-000038 · form4.xml · derivative · entry 4

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,250

Underlying: Common Stock · 14,000 shares

Expires 2027-12-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The options vested 100% on December 14, 2018.

SEC source: 0001133416-25-000038 · form4.xml · nonDerivative · entry 2

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 832,592

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F2 · price: The shares were sold in multiple transactions at prices ranging from $6.331 to $6.51. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001133416-25-000038 · form4.xml · nonDerivative · entry 1

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 846,592

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

SEC source: 0001133416-25-000035 · form4.xml · nonDerivative · entry 1

ELDRED KARY · CIK 0001543425 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,682

SEC source: 0001133416-25-000033 · form4.xml · nonDerivative · entry 1

FREEMAN KEVIN D · CIK 0001522478 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,769

SEC source: 0001641172-25-014756 · ownership.xml · derivative · entry 19

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2025-06-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Stock options were exercisable at time of exercise.

SEC source: 0001641172-25-014756 · ownership.xml · derivative · entry 18

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2025-06-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Stock options were exercisable at time of exercise.

SEC source: 0001641172-25-014756 · ownership.xml · derivative · entry 17

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 70,000 shares

Expires 2025-06-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Stock options were exercisable at time of exercise.

SEC source: 0001641172-25-014756 · ownership.xml · derivative · entry 16

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 40,000 shares

Expires 2025-06-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Stock options were exercisable at time of exercise.

SEC source: 0001641172-25-014756 · ownership.xml · derivative · entry 15

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,000

Underlying: Common Stock · 30,000 shares

Expires 2025-06-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Stock options were exercisable at time of exercise.

SEC source: 0001641172-25-014756 · ownership.xml · derivative · entry 14

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,000

Underlying: Common Stock · 25,000 shares

Expires 2025-06-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Stock options were exercisable at time of exercise.

SEC source: 0001641172-25-014756 · ownership.xml · derivative · entry 13

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 245,000

Underlying: Common Stock · 46,875 shares

Expires 2025-06-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Stock options were exercisable at time of exercise.

SEC source: 0001641172-25-014756 · ownership.xml · derivative · entry 12

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 291,875

Underlying: Common Stock · 31,250 shares

Expires 2025-06-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Stock options were exercisable at time of exercise.

SEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 11

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,045,541

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 10

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,005,541

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 9

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 965,541

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 8

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 895,541

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 7

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 855,541

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 6

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 825,541

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 5

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 800,541

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 4

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 753,666

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 3

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 722,416

F1 · kind: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividend was paid on 3/31/2025. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend.

F2 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9.

F1 · price: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividend was paid on 3/31/2025. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend.

SEC source: 0001133416-25-000029 · form4.xml · nonDerivative · entry 1

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 832,592

F1 · security: Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units ("DSUs") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs from the amended agreement shall be settled in shares of Common Stock as follows: (i) fifty percent shall be settled on March 1, 2025 and (ii) fifty percent shall be settled on January 5, 2026.

F3 · shares: Represents shares withheld from issuance to Mr. Lewis for federal and state withholding taxes on income.

F2 · balance_after: Represents shares underlying DSUs and Common Stock.

SEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 2

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 721,416

F3 · price: No consideration was received for the shares, which were transferred by gift to relatives.

SEC source: 0001641172-25-014756 · ownership.xml · nonDerivative · entry 1

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 731,416

F3 · price: No consideration was received for the shares, which were transferred by gift to relatives.

SEC source: 0001133416-25-000006 · form4.xml · derivative · entry 1

CARSON BENJAMIN SR · CIK 0000017940 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2035-01-23

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2025.

SEC source: 0001133416-25-000024 · form4.xml · derivative · entry 1

Zordani Richard A. Jr. · CIK 0001827180 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2035-01-23

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2025.

SEC source: 0001133416-25-000022 · form4.xml · derivative · entry 3

Uihlein Richard E · CIK 0001694903 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2035-01-23

F3 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F4 · derivative.exercise_date: The options vest 100% on December 31, 2025.

SEC source: 0001133416-25-000022 · form4.xml · nonDerivative · entry 1

Uihlein Richard E · CIK 0001694903 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,301,271

F1 · shares: These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2024. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2024.

SEC source: 0001133416-25-000020 · form4.xml · derivative · entry 1

Schwartz Elissa J. · CIK 0001827177 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2035-01-23

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2025.

SEC source: 0001133416-25-000018 · form4.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2035-01-23

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2025.

SEC source: 0001133416-25-000016 · form4.xml · derivative · entry 1

OMENN GILBERT S · CIK 0001184227 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2035-01-23

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2025.

SEC source: 0001133416-25-000014 · form4.xml · derivative · entry 2

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,000

Underlying: Common Stock · 84,000 shares

Expires not disclosed

F3 · derivative.exercise_price: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.

F4 · derivative.exercise_date: Restricted Stock Units vest upon the earlier of December 31, 2025 or signing a partnership agreement.

F4 · derivative.expiration_date: Restricted Stock Units vest upon the earlier of December 31, 2025 or signing a partnership agreement.

SEC source: 0001133416-25-000014 · form4.xml · derivative · entry 1

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,000

Underlying: Common Stock · 91,000 shares

Expires 2035-01-23

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2025; December 31, 2025; June 30, 2026; and December 31, 2026.

SEC source: 0001133416-25-000012 · form4.xml · derivative · entry 2

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires not disclosed

F4 · derivative.exercise_price: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.

F3 · derivative.exercise_date: Restricted Stock Units vest 100% on the earlier of December 31, 2025 or signing of a partnership agreement.

F3 · derivative.expiration_date: Restricted Stock Units vest 100% on the earlier of December 31, 2025 or signing of a partnership agreement.

SEC source: 0001133416-25-000012 · form4.xml · derivative · entry 1

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2035-01-23

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2025; December 31, 2025; June 30, 2026; and December 31, 2026.

SEC source: 0001133416-25-000010 · form4.xml · derivative · entry 1

FREEMAN KEVIN D · CIK 0001522478 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2035-01-23

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2025.

SEC source: 0001133416-25-000008 · form4.xml · derivative · entry 1

ELDRED KARY · CIK 0001543425 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2035-01-23

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2025.

SEC source: 0001133416-25-000004 · form4.xml · derivative · entry 2

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires not disclosed

F4 · derivative.exercise_price: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.

F3 · derivative.exercise_date: Restricted Stock Units vest 100% on the earlier of December 31, 2025 or signing of a partnership agreement.

F3 · derivative.expiration_date: Restricted Stock Units vest 100% on the earlier of December 31, 2025 or signing of a partnership agreement.

SEC source: 0001133416-25-000004 · form4.xml · derivative · entry 1

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2035-01-23

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2025; December 31, 2025; June 30, 2026; and December 31, 2026.

SEC source: 0001133416-25-000002 · form4.xml · derivative · entry 1

OMENN GILBERT S · CIK 0001184227 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2035-01-23

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2025.

SEC source: 0001133416-25-000026 · form4.xml · derivative · entry 1

Shlevin Harold H. · CIK 0001557082 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: comm Stock · 60,000 shares

Expires 2035-01-23

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2025.

SEC source: 0001133416-24-000074 · form4.xml · nonDerivative · entry 1

Shlevin Harold H. · CIK 0001557082 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,206

SEC source: 0001133416-24-000066 · form4.xml · nonDerivative · entry 1

Zordani Richard A. Jr. · CIK 0001827180 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,083

SEC source: 0001133416-24-000064 · form4.xml · nonDerivative · entry 1

ELDRED KARY · CIK 0001543425 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,682

SEC source: 0001133416-24-000062 · form4.xml · nonDerivative · entry 1

FREEMAN KEVIN D · CIK 0001522478 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,769